Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Baxter
Citi
Daiichi Sankyo
Deloitte
Chinese Patent Office
UBS
Moodys
US Department of Justice
AstraZeneca

Generated: October 20, 2017

DrugPatentWatch Database Preview

CANASA Drug Profile

« Back to Dashboard

What is the patent landscape for Canasa, and what generic Canasa alternatives are available?

Canasa is a drug marketed by Forest Labs Llc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in twelve countries.

The generic ingredient in CANASA is mesalamine. There are twenty-eight drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

Summary for Tradename: CANASA

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list113
Clinical Trials: see list2
Patent Applications: see list5,539
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CANASA at DailyMed

Pharmacology for Tradename: CANASA

Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Llc
CANASA
mesalamine
SUPPOSITORY;RECTAL021252-002Nov 5, 2004ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Forest Labs Llc
CANASA
mesalamine
SUPPOSITORY;RECTAL021252-002Nov 5, 2004ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Forest Labs Llc
CANASA
mesalamine
SUPPOSITORY;RECTAL021252-001Jan 5, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for CANASA

Drugname Dosage Strength RLD Submissiondate
mesalamineSuppository1000 mgCanasa5/24/2013

Non-Orange Book Patents for Tradename: CANASA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,541,384Mesalamine suppository► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CANASA

Country Document Number Estimated Expiration
Singapore181169► Subscribe
World Intellectual Property Organization (WIPO)2011084638► Subscribe
Canada2784772► Subscribe
Canada2690450► Subscribe
Singapore181169► Subscribe
South Korea20120104604► Subscribe
European Patent Office2512443► Subscribe
South Korea20120104604► Subscribe
Canada2784772► Subscribe
China102970971► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Medtronic
Cerilliant
Merck
Citi
Johnson and Johnson
Chubb
Baxter
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot